Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/72710
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2021-04-01T07:04:57Z-
dc.date.available2021-04-01T07:04:57Z-
dc.date.issued2020-
dc.identifier.citationLangaro, M. (2020). Innovative regulatory framework in community pharmacy (Doctoral dissertation).en_GB
dc.identifier.urihttps://www.um.edu.mt/library/oar/handle/123456789/72710-
dc.descriptionPharmDen_GB
dc.description.abstractThe implementation of Good Pharmacy Practice (GPP) in Malta and the evolution of pharmacy regulatory science led to an innovative patient-centred approach in regulatory audit. The aim of the research is to establish a regulatory self-audit model in community pharmacy aiming at satisfying regulatory requirements while meeting patient needs. The methodology included (1) an analysis of the regulatory framework by a multidisciplinary focus group (n=3 patients, n=3 general practitioners, n=3 pharmacists), (2) design and validation of the self-audit protocol, (3) risk-based assessment defining regulatory criteria (N=76) as minor, major and critical and correspondingly classifying pharmacies in high (1 critical or above 5 major findings), medium (1-5 major) and low risk (only minor findings) categories, (4) competencies and regulatory self-audits and regulatory audits in 61 community pharmacies, (5) measurement of compliance agreement between regulatory and self-audits and of risk categorisation with the Kappa test, mean percentage compliance with the Wilcoxon Signed Ranks test (6) correlations between pharmacist characteristics and self-audit results with the Chi square test. (1) The focus group analysis optimised the methodology of the research by identifying 4 risk factors (resistance for the observation of patient-pharmacist interactions, oversights of legal requirements, need for higher pharmacist competencies and pharmacist work overload), 2 weaknesses (unacceptability of proactive initiatives by the pharmacist, lack of robustness in the self-audit) and 5 strengths (optimisation of clinical service, recognition of pharmacist’s role, reduction in redundant bureaucracy, meeting patient needs, personalised healthcare). (2) The self-audit protocol assessed pharmacist strengths, scientific interests, goals and opportunities for improvement, and regulatory criteria through a regulatory checklist. (3) The risk assessment identified 19 minor, 34 major and 23 critical regulatory criteria. (4) Pharmacists (34 female, mean age 43, range 25-73) reported ‘understanding patient needs’ (57.4%) and ‘patient-orientation’ (49.2%) as the two highest strengths, ‘personalised healthcare’ (44.3%) as the major area of interest, ‘service optimisation’ (49.5%) as the main goal and ‘continuous education’ (63.9%) as an opportunity for improvement. In the self-audits pharmacies reported higher regulatory compliance (94.7% ± 4.65) and were classified in lower risk-categories (low-risk=27, medium-risk=18, high-risk pharmacies=16) than in regulatory audits (82.7% ± 8.14; lowrisk= 2, medium-risk=13, high-risk pharmacies=46). Agreement between regulatory and self-audits was achieved for 9 out 76 criteria (p-value<0.05). The difference on mean percentage compliance between regulatory and self-audits was statistically significant (p=0.000) while agreement on regulatory and self-audits risk categorisation was not achieved (Kappa= 0.050, p=0.395). (5) ‘Understanding patient needs’ and ‘good communication skills’ were reported as main strengths by 67.6% and 47% of the pharmacists with more than 6 years of experience (p=0.000). Pharmacists below-30 and over-60 years-old assigned a lower regulatory self-audit risk compared to intermediate age-categories (p-value=0.041). A self-audit showed highly significant differences from the established regulatory audit. A less policing approach in audits may lead to achieve concordance between regulation and pharmacy practice. A GPP certificate based on pharmacist competencies, on regulatory compliance and on a pharmacy-risk analysis is proposed to addresses pharmacy educational needs and optimise pharmacy practice towards meeting patient needs.en_GB
dc.language.isoenen_GB
dc.rightsinfo:eu-repo/semantics/openAccessen_GB
dc.subjectPharmaceutical services -- Maltaen_GB
dc.subjectPrimary care (Medicine) -- Maltaen_GB
dc.subjectPharmacist and patient -- Maltaen_GB
dc.subjectSelf-evaluation -- Maltaen_GB
dc.subjectPharmacy -- Malta -- Auditingen_GB
dc.titleInnovative regulatory framework in community pharmacyen_GB
dc.typedoctoralThesisen_GB
dc.rights.holderThe copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder.en_GB
dc.publisher.institutionUniversity of Maltaen_GB
dc.publisher.departmentFaculty of Medicine and Surgery. Department of Pharmacyen_GB
dc.description.reviewedN/Aen_GB
dc.contributor.creatorLangaro, Marina (2020)-
Appears in Collections:Dissertations - FacM&S - 2020
Dissertations - FacM&SPha - 2020

Files in This Item:
File Description SizeFormat 
MARINA LANGARO.pdf2.8 MBAdobe PDFView/Open


Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.